|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
US20050142141A1
(en)
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
AU2003286870A1
(en)
|
2003-06-05 |
2005-01-04 |
Salk Institute For Biological Studies |
Targeting polypeptides to the central nervous system
|
|
PL3219795T3
(pl)
|
2008-01-18 |
2024-09-16 |
Biomarin Pharmaceutical Inc. |
Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
|
|
EP2394667A1
(en)
|
2010-06-10 |
2011-12-14 |
Laboratorios Del Dr. Esteve, S.A. |
Vectors and sequences for the treatment of diseases
|
|
BR112012033214B1
(pt)
|
2010-06-25 |
2020-11-03 |
Shire Human Genetic Therapies, Inc. |
uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
|
|
JP6073783B2
(ja)
|
2010-06-25 |
2017-02-01 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
CA2842492A1
(en)
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
|
WO2014022515A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
MX367126B
(es)
|
2012-08-29 |
2019-08-06 |
Hoffmann La Roche |
Transporte para atravesar la barrera hematoencefálica.
|
|
NZ711373A
(en)
|
2013-03-13 |
2020-07-31 |
Bioasis Technologies Inc |
Fragments of p97 and uses thereof
|
|
WO2014152940A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
US20150023956A1
(en)
|
2013-07-22 |
2015-01-22 |
Armagen Technologies, Inc. |
Methods and compositions for increasing enzyme activity in the cns
|
|
SMT201800511T1
(it)
|
2014-04-01 |
2018-11-09 |
Swedish Orphan Biovitrum Ab Publ |
Sulfamidasi modificata e sua produzione
|
|
PT3215528T
(pt)
|
2014-11-06 |
2019-10-11 |
Hoffmann La Roche |
Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
CA2990785C
(en)
|
2015-06-24 |
2024-11-12 |
Jcr Pharmaceuticals Co., Ltd. |
ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
|
|
AU2016282334B2
(en)
|
2015-06-24 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
|
EP3419651B1
(en)
|
2016-02-24 |
2023-10-25 |
BioMarin Pharmaceutical Inc. |
Improved naglu fusion protein formulation
|
|
CA3033082A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
CN109641971B
(zh)
|
2016-08-25 |
2023-04-04 |
Jcr制药股份有限公司 |
抗体融合蛋白的制造方法
|
|
EP3556399A1
(en)
|
2016-12-19 |
2019-10-23 |
Hanmi Pharm. Co., Ltd. |
Brain targeting long-acting protein conjugate
|
|
TWI833178B
(zh)
*
|
2016-12-26 |
2024-02-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
MX2019007824A
(es)
|
2016-12-28 |
2019-09-09 |
Japan Chem Res |
Preparacion liofilizada.
|
|
RS63818B1
(sr)
|
2017-02-17 |
2023-01-31 |
Denali Therapeutics Inc |
Konstruisani polipeptidi za vezivanje za receptor transferina
|
|
CA3053379A1
(en)
|
2017-02-17 |
2018-08-23 |
Denali Therapeutics Inc. |
Anti-tau antibodies and methods of use thereof
|
|
EP4628586A3
(en)
|
2017-02-17 |
2026-01-14 |
Denali Therapeutics Inc. |
Transferrin receptor transgenic models
|
|
GB201702863D0
(en)
|
2017-02-22 |
2017-04-05 |
Evox Therapeutics Ltd |
Improved loading of EVs with therapeutic proteins
|
|
US20200157172A1
(en)
|
2017-07-07 |
2020-05-21 |
HANMl PHARM. CO., LTD. |
Novel therapeutic enzyme fusion protein and use thereof
|
|
WO2019032955A1
(en)
|
2017-08-10 |
2019-02-14 |
Denali Therapeutics Inc. |
MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
|
|
BR112020005271A2
(pt)
|
2017-10-02 |
2020-09-15 |
Denali Therapeutics Inc. |
proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
|
|
WO2019094608A1
(en)
|
2017-11-08 |
2019-05-16 |
Denali Therapeutics Inc. |
Anti-bace1 antibodies and methods of use thereof
|
|
EP3708661A4
(en)
|
2017-12-22 |
2021-12-01 |
Hanmi Pharm. Co., Ltd. |
THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
|
|
BR112020013921A2
(pt)
*
|
2018-01-10 |
2020-12-01 |
Denali Therapeutics Inc. |
polipeptídeos de ligação ao receptor de transferrina e usos destes
|
|
WO2019145500A1
(en)
|
2018-01-26 |
2019-08-01 |
Swedish Orphan Biovitrum Ab (Publ) |
Method of treatment
|
|
CR20200566A
(es)
*
|
2018-05-25 |
2021-02-19 |
Alector Llc |
Anticuerpos anti-sirpa y metodos de utilización de los mismos
|
|
WO2019246071A1
(en)
|
2018-06-18 |
2019-12-26 |
Denali Therapeutics Inc. |
Fusion proteins comprising progranulin
|
|
CA3109763A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Denali Therapeutics Inc. |
Engineered bispecific proteins
|
|
EP3840781A1
(en)
|
2018-08-22 |
2021-06-30 |
Denali Therapeutics Inc. |
Anti-her2 polypeptides and methods of use thereof
|
|
AR119259A1
(es)
*
|
2018-08-31 |
2021-12-09 |
Alector Llc |
Anticuerpos anti-cd33 y métodos de uso de los mismos
|
|
AU2020252554B2
(en)
|
2019-04-03 |
2026-05-28 |
Denali Therapeutics Inc. |
Formulations of protein molecules comprising iduronate 2-sulfatase
|
|
BR112022012230A2
(pt)
|
2019-12-23 |
2022-08-30 |
Denali Therapeutics Inc |
Variantes de progranulina
|
|
US11124567B2
(en)
|
2020-01-13 |
2021-09-21 |
Denali Therapeutics Inc. |
Anti-TREM2 antibodies and methods of use thereof
|
|
WO2021146256A1
(en)
|
2020-01-13 |
2021-07-22 |
Denali Therapeutics Inc. |
Anti-trem2 antibodies and methods of use thereof
|
|
WO2021158986A1
(en)
|
2020-02-07 |
2021-08-12 |
Denali Therapeutics Inc. |
Methods for the treatment of hunter syndrome
|
|
CA3170338A1
(en)
|
2020-02-19 |
2021-08-26 |
Denali Therapeutics Inc. |
Engineered anti-her2 bispecific proteins
|